Skip to main content
main-content

01.12.2017 | Review | Ausgabe 1/2017 Open Access

World Journal of Surgical Oncology 1/2017

The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature

Zeitschrift:
World Journal of Surgical Oncology > Ausgabe 1/2017
Autoren:
Yu-ying Lei, Jin-yu Huang, Qiong-rui Zhao, Nan Jiang, Hui-mian Xu, Zhen-ning Wang, Hai-qing Li, Shi-bo Zhang, Zhe Sun
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​s12957-017-1132-5) contains supplementary material, which is available to authorized users.

Abstract

Background

Human epidermal growth factor receptor-2 (HER2) is regarded as an important and promising target in the treatment of HER2-positive breast cancers. However, the correlation of clinicopathological characteristics and prognostic significance of HER2 overexpression in gastric cancer patients remains unclear. Our aim was to clarify this issue.

Methods

Embase, PubMed, and the Cochrane Library were searched for relevant articles published up to May 2016. Outcomes of interest contained sex, age, tumor size, tumor site, tumor node metastasis (TNM) stage, distant metastasis, lymph node metastasis, Lauren’s classification, differentiation grade, lymphovascular invasion, neural invasion, and multivariate analysis data for overall survival.

Results

A total of 41 studies of 17,494 gastric cancer patients were identified with HER2 test. HER2 positive rate was 19.07% (95% CI = 9.16, 28.98). There existed statistical significance between HER2 overexpression and patients’ prognosis (RR = 1.47, 95% CI = 1.09, 1.98). Male patients (OR = 1.48, 95% CI = 1.34, 1.65), proximal tumors (OR = 1.25, 95% CI = 1.07, 1.47), intestinal-type tumors (OR = 3.37, 95% CI = 2.54, 4.47), advanced stage cancers (OR = 1.35, 95% CI = 1.10, 1.66), lymph node metastasis (OR = 1.26, 95% CI = 1.14, 1.41), well-differentiated cancers (OR = 1.79, 95% CI = 1.15, 2.76), and distant metastasis (OR = 1.91, 95% CI = 1.08, 3.38) were correlated with higher HER2 expression rates. However, no statistical differences existed in age, tumor size, lymphovascular invasion, or neural invasion. Subgroup analysis revealed that HER2 expression rates reported in articles from Asian (19.52%) countries were quantitatively higher than those from European (16.91%) areas. Results were consistent with those reports that define HER2 status according to trastuzumab for gastric cancer (ToGA) criteria.

Conclusion

This study showed that HER2 overexpression was associated with poor prognosis in gastric cancer patients. HER2 positive rates may be associated with sex, tumor site, TNM staging system, distant metastasis, lymph node metastasis, Lauren’s classification, and differentiation grade in gastric cancer patients. The HER2 expression rate in Asians may be higher than that in Europeans. This study offers a convenient way for doctors to select patients for relevant HER2 detection and following treatment.
Zusatzmaterial
Additional file 1: Baseline characteristics of included studies. (DOCX 29 kb)
12957_2017_1132_MOESM1_ESM.docx
Additional file 2: Newcastle–Ottawa Scale (NOS) Table: methodological quality of cohort studies included in the meta-analysis*. (DOC 95 kb)
12957_2017_1132_MOESM2_ESM.doc
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2017

World Journal of Surgical Oncology 1/2017 Zur Ausgabe

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise